spinifex
Novartis spends $200m on pain firm Spinifex
June 29, 2015Sales and Marketing Cosentyx, EMA401, Novartis, Secukinumab, spinifex
Novartis is spending $200 million to increase its presence in pain management through the purchase of US-Australian biotech Spinifex Pharmaceuticals. …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
